Literature DB >> 11145701

Role of C5a in multiorgan failure during sepsis.

M Huber-Lang1, V J Sarma, K T Lu, S R McGuire, V A Padgaonkar, R F Guo, E M Younkin, R G Kunkel, J Ding, R Erickson, J T Curnutte, P A Ward.   

Abstract

In humans with sepsis, the onset of multiorgan failure (MOF), especially involving liver, lungs, and kidneys, is a well known complication that is associated with a high mortality rate. Our previous studies with the cecal ligation/puncture (CLP) model of sepsis in rats have revealed a C5a-induced defect in the respiratory burst of neutrophils. In the current CLP studies, MOF occurred during the first 48 h with development of liver dysfunction and pulmonary dysfunction (falling arterial partial pressure of O(2), rising partial pressure of CO(2)). In this model an early respiratory alkalosis developed, followed by a metabolic acidosis with increased levels of blood lactate. During these events, blood neutrophils lost their chemotactic responsiveness both to C5a and to the bacterial chemotaxin, fMLP. Neutrophil dysfunction was associated with virtually complete loss in binding of C5a, but binding of fMLP remained normal. If CLP animals were treated with anti-C5a, indicators of MOF and lactate acidosis were greatly attenuated. Under the same conditions, C5a binding to blood neutrophils remained intact; in tandem, in vitro chemotactic responses to C5a and fMLP were retained. These data suggest that, in the CLP model of sepsis, treatment with anti-C5a prevents development of MOF and the accompanying onset of blood neutrophil dysfunction. This may explain the protective effects of anti-C5a in the CLP model of sepsis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145701     DOI: 10.4049/jimmunol.166.2.1193

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

Review 1.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Complement-induced impairment of the innate immune system during sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

3.  Early complementopathy after multiple injuries in humans.

Authors:  Anne-Maud Burk; Myriam Martin; Michael A Flierl; Daniel Rittirsch; Matthias Helm; Lorenz Lampl; Uwe Bruckner; Gregory L Stahl; Anna M Blom; Mario Perl; Florian Gebhard; Markus Huber-Lang
Journal:  Shock       Date:  2012-04       Impact factor: 3.454

4.  Is the function of alveolar macrophages altered following blunt chest trauma?

Authors:  Ulrich C Liener; Mario Perl; Markus S Huber-Lang; Daniel H Seitz; Uwe B Brückner; Florian Gebhard; Markus W Knöferl
Journal:  Langenbecks Arch Surg       Date:  2011-02       Impact factor: 3.445

Review 5.  Differential Paradigms in Animal Models of Sepsis.

Authors:  S Manoj Kumar Kingsley; B Vishnu Bhat
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

6.  Do MDL-1⁺ cells play a broad role in acute inflammation?

Authors:  Peter A Ward
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

7.  Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance.

Authors:  Erin C Conrad; Yueh-Ya Hsu; David M Bortz; John G Younger
Journal:  J Innate Immun       Date:  2013-01-11       Impact factor: 7.349

8.  Complement-induced Impairment of the Innate Immune System During Sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 9.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro.

Authors:  Miriam Kalbitz; Fatemeh Fattahi; Todd J Herron; Jamison J Grailer; Lawrence Jajou; Hope Lu; Markus Huber-Lang; Firas S Zetoune; J Vidya Sarma; Sharlene M Day; Mark W Russell; José Jalife; Peter A Ward
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.